- Home
- JFBR vs BTAI Comparison
JFBR vs BTAI Comparison
Compare JFBR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JFBR | BTAI |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Israel | United States |
| Employees | 11 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 35.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JFBR | BTAI |
|---|---|---|
| Price | $3.72 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.25 |
| AVG Volume (30 Days) | 23.8K | ★ 1.2M |
| Earning Date | 03-31-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.17 |
| 52 Week High | $7.87 | $8.08 |
Technical Indicators
Market Signals| Indicator | JFBR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 41.98 |
| Support Level | $3.58 | $1.44 |
| Resistance Level | $5.40 | $2.22 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 6.06 | 3.95 |
Price Performance
Historical ComparisonAbout JFBR Jeffs' Brands Ltd
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.